Charmi Patel

601 total citations · 1 hit paper
32 papers, 303 citations indexed

About

Charmi Patel is a scholar working on Psychiatry and Mental health, Social Psychology and Economics and Econometrics. According to data from OpenAlex, Charmi Patel has authored 32 papers receiving a total of 303 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Psychiatry and Mental health, 14 papers in Social Psychology and 10 papers in Economics and Econometrics. Recurrent topics in Charmi Patel's work include Schizophrenia research and treatment (28 papers), Mental Health Treatment and Access (14 papers) and Health Systems, Economic Evaluations, Quality of Life (9 papers). Charmi Patel is often cited by papers focused on Schizophrenia research and treatment (28 papers), Mental Health Treatment and Access (14 papers) and Health Systems, Economic Evaluations, Quality of Life (9 papers). Charmi Patel collaborates with scholars based in United States, Canada and Germany. Charmi Patel's co-authors include Carmela Benson, Kruti Joshi, Edward Kim, Christoph U. Correll, Patrick Lefèbvre, Amber Martin, Rebecca Goulding, Marie‐Hélène Lafeuille, Bruno Émond and Laura Morrison and has published in prestigious journals such as SHILAP Revista de lepidopterología, Psychiatric Services and BMC Health Services Research.

In The Last Decade

Charmi Patel

30 papers receiving 297 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics

2022 96 citations Christoph U. Correll, Amber Martin et al. SHILAP Revista de lepidopterología profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Charmi Patel United States	10	255	80	61	54	40	32	303
Mallik Greene United States	11	455 1.8×	64 0.8×	66 1.1×	92 1.7×	39 1.0×	49	563
Rhiannon Kamstra United States	8	223 0.9×	55 0.7×	79 1.3×	44 0.8×	55 1.4×	25	375
Fuminari Misawa Japan	9	431 1.7×	90 1.1×	24 0.4×	93 1.7×	16 0.4×	28	488
Ralph Aquila United States	10	357 1.4×	77 1.0×	41 0.7×	111 2.1×	41 1.0×	15	446
L. Hargarter Germany	12	453 1.8×	147 1.8×	33 0.5×	151 2.8×	25 0.6×	33	497
Desiree Castillo United States	5	310 1.2×	85 1.1×	46 0.8×	103 1.9×	21 0.5×	9	374
Dolores Keating Ireland	8	203 0.8×	65 0.8×	34 0.6×	52 1.0×	11 0.3×	23	275
Maila Majak Sweden	6	581 2.3×	172 2.1×	91 1.5×	176 3.3×	42 1.1×	8	734
F Casadebaig France	9	370 1.5×	98 1.2×	105 1.7×	125 2.3×	29 0.7×	23	505
Patricia L. Gilbert United States	3	305 1.2×	95 1.2×	25 0.4×	101 1.9×	25 0.6×	5	352

Countries citing papers authored by Charmi Patel

Since Specialization

Citations

This map shows the geographic impact of Charmi Patel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charmi Patel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charmi Patel more than expected).

Fields of papers citing papers by Charmi Patel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charmi Patel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charmi Patel. The network helps show where Charmi Patel may publish in the future.

Co-authorship network of co-authors of Charmi Patel

This figure shows the co-authorship network connecting the top 25 collaborators of Charmi Patel. A scholar is included among the top collaborators of Charmi Patel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charmi Patel. Charmi Patel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Pengxiang, Zhi Geng, Carmela Benson, Charmi Patel, & Jalpa A. Doshi. (2025). Real-World Effectiveness of Long-Acting Injectable and Oral Antipsychotic Agents in US Medicare Patients with Schizophrenia. Advances in Therapy. 42(2). 1251–1264. 2 indexed citations

Cai, Chao, Chris M Kozma, Charmi Patel, et al.. (2024). Adherence, health care utilization, and costs between long-acting injectable and oral antipsychotic medications in South Carolina Medicaid beneficiaries with schizophrenia. Journal of Managed Care & Specialty Pharmacy. 30(6). 549–559. 4 indexed citations

Li, Pengxiang, et al.. (2023). Antipsychotic utilization, healthcare resource use and costs, and quality of care among fee-for-service Medicare beneficiaries with schizophrenia in the United States. Journal of Medical Economics. 26(1). 525–536. 9 indexed citations

Basu, Anirban, et al.. (2023). Real-world calibration and transportability of the Disease Recovery Evaluation and Modification (DREaM) randomized clinical trial in adult Medicaid beneficiaries with recent-onset schizophrenia. Journal of Managed Care & Specialty Pharmacy. 29(3). 293–302. 1 indexed citations

Correll, Christoph U., Carmela Benson, Bruno Émond, et al.. (2023). Comparison of clinical outcomes in patients with schizophrenia following different long-acting injectable event-driven initiation strategies. Schizophrenia. 9(1). 9–9. 11 indexed citations

Patel, Charmi, et al.. (2023). Post Hospitalization Clinical Quality Outcomes Among US Patients with Schizophrenia Treated with a Long-Acting Injectable or Switched to a New Oral Antipsychotic: A Retrospective Cohort Study. Drugs - Real World Outcomes. 11(1). 69–79.

Doshi, Jalpa A., et al.. (2023). Out-of-Pocket Costs for Long-Acting Injectable and Oral Antipsychotics Among Medicare Patients With Schizophrenia. Psychiatric Services. 75(4). 333–341. 5 indexed citations

Patel, Charmi, et al.. (2022). Adherence, Persistence, Readmissions, and Costs in Medicaid Members with Schizophrenia or Schizoaffective Disorder Initiating Paliperidone Palmitate Versus Switching Oral Antipsychotics: A Real-World Retrospective Investigation. Advances in Therapy. 40(1). 349–366. 9 indexed citations

Correll, Christoph U., Amber Martin, Charmi Patel, et al.. (2022). Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics. SHILAP Revista de lepidopterología. 8(1). 5–5. 96 indexed citations breakdown →

10.

Patel, Charmi, et al.. (2022). Patient Journey of Veterans with Schizophrenia: An Analysis of Treatment Patterns, Healthcare Resource Utilization and Costs. Advances in Therapy. 39(3). 1199–1214. 2 indexed citations

11.

Pesa, Jacqueline, Charmi Patel, David Rotter, et al.. (2021). Economic burden to commercial payers of young adults with schizophrenia in Colorado. Journal of Medical Economics. 24(1). 1194–1203. 1 indexed citations

12.

Khoury, Antoine C. El, et al.. (2021). Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia. Neuropsychiatric Disease and Treatment. Volume 17. 3159–3170. 3 indexed citations

13.

Lin, Dee, Jesse Fishman, Timothy Hetherington, et al.. (2021). The Impact of Once-Monthly Paliperidone Palmitate on Healthcare Utilization Among Patients With Schizophrenia Treated in an Integrated Healthcare System: A Retrospective Mirror-Image Study. Advances in Therapy. 38(4). 1958–1974. 9 indexed citations

14.

Blonde, Lawrence, Charmi Patel, Bingcao Wu, et al.. (2020). Real-World Comparative Effectiveness of Canagliflozin Versus Empagliflozin and Dapagliflozin in Patients with Type 2 Diabetes in the United States. Advances in Therapy. 38(1). 594–606. 7 indexed citations

15.

Patel, Charmi, et al.. (2020). Healthcare Resource Utilization and Costs Among Patients With Schizophrenia Switching From Oral Risperidone/Paliperidone to Once-Monthly Paliperidone Palmitate: A Veterans Health Administration Claims Analysis. Current Therapeutic Research. 92. 100587–100587. 8 indexed citations

16.

Pilon, Dominic, Charmi Patel, Marie‐Hélène Lafeuille, et al.. (2020). PMH17 ECONOMIC BURDEN OF MEDICAID BENEFICIARIES WITH SCHIZOPHRENIA NOT ADHERENT TO ANTIPSYCHOTICS AND WITH SCHIZOPHRENIA RELAPSES. Value in Health. 23. S203–S203.

17.

Patel, Charmi, Bruno Émond, Marie‐Hélène Lafeuille, et al.. (2019). Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate. Drugs - Real World Outcomes. 7(1). 19–29. 22 indexed citations

18.

Cai, Qian, et al.. (2019). Factors Associated with the Initiation of Long-Acting Injectable Paliperidone Palmitate Versus Aripiprazole Among Medicaid Patients with Schizophrenia: An Observational Study. Advances in Therapy. 36(4). 858–869. 2 indexed citations

19.

Patel, Charmi, et al.. (2019). Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective Analysis. Advances in Therapy. 36(10). 2941–2953. 5 indexed citations

20.

Patel, Charmi, Robert A. Bailey, Ujjwala Vijapurkar, Gary Meininger, & Lawrence Blonde. (2016). A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures. BMC Health Services Research. 16(1). 356–356. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact